PolyNovo Limited (ASX: PNV), a disruptive medical device company specializing in advanced wound care solutions, has achieved a remarkable milestone by reporting an unprecedented monthly sale of AU$7.2 million (unaudited) for May. PolyNovo designs, develops, and manufactures cutting-edge dermal regeneration solutions. The record-breaking sales results are attributed to exceptional performance in key markets. In the United States, monthly sales reached an impressive AU$5.2 million (unaudited), showing a remarkable growth of 97.3% compared to the same period last year.
The rest of the world also experienced significant growth, with record monthly sales of AU$1.9 million (unaudited), marking a substantial increase of 189.3% compared to STLY. Notable achievements include robust sales in Canada, Hong Kong, and India, as well as securing a first-time order from the Middle East. Overall, the total revenue (unaudited) for the 11-month period ending on 31 May, 2023, stands at AU$59.1 million, reflecting a notable growth of 54.5% compared to STLY's AU$38.3 million.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
